Edition:
United Kingdom

Iovance Biotherapeutics Inc (IOVA.OQ)

IOVA.OQ on NASDAQ Stock Exchange Global Market

17.95USD
16 Feb 2018
Change (% chg)

$0.55 (+3.16%)
Prev Close
$17.40
Open
$17.40
Day's High
$18.30
Day's Low
$17.40
Volume
188,742
Avg. Vol
185,786
52-wk High
$18.30
52-wk Low
$4.45

Select another date:

Thu, Jan 25 2018

BRIEF-Iovance Biotherapeutics Announces Pricing Of Its Public Offering Of $150 Million Of Common Stock

* IOVANCE BIOTHERAPEUTICS, INC. ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF $150 MILLION OF COMMON STOCK

BRIEF-Iovance Announces Preliminary Phase 2 Data For Til Treatment In Head And Neck And Cervical Cancers

* IOVANCE BIOTHERAPEUTICS ANNOUNCES PRELIMINARY PHASE 2 DATA FOR TIL TREATMENT IN HEAD AND NECK AND CERVICAL CANCERS

BRIEF-Iovance Biotherapeutics‍ Intends To Offer And Sell $125 Mln Of Its Common Stock

* IOVANCE BIOTHERAPEUTICS, INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Iovance Biotherapeutics Files For Mixed Shelf Of Up To $250 Mln

* IOVANCE BIOTHERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING Source text: (http://bit.ly/2zKJhqw) Further company coverage:

BRIEF-Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates

* IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017

BRIEF-Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35

* Iovance Biotherapeutics Inc reports third quarter 2017 financial results

BRIEF-Iovance Biotherapeutics announces pricing of its public offering of $50 mln of common stock

* Iovance Biotherapeutics, Inc. announces pricing of its public offering of $50 million of common stock

BRIEF-Iovance BioTherapeutics plans to offer $50 mln of common stock​

* Intends to use proceeds from this offering to fund its ongoing clinical trials for its current candidates​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Iovance Biotherapeutics announces approval of 1st clinical trial of LN-145 for treating cervical cancer

* Iovance Biotherapeutics announces approval of first clinical trial application by competent authority in Netherlands for a phase 2 trial of LN-145 for the treatment of patients with cervical cancer Source text for Eikon: Further company coverage:

BRIEF-Iovance Biotherapeutics enters into a research collaboration with the Ohio State University Comprehensive Cancer Center

* Iovance Biotherapeutics enters into a research collaboration focused on hematologic malignancies with the Ohio State University Comprehensive Cancer Center

Select another date: